BRPI0413906A - composições imunogênicas de hiv, kit e métodos relacionados - Google Patents
composições imunogênicas de hiv, kit e métodos relacionadosInfo
- Publication number
- BRPI0413906A BRPI0413906A BRPI0413906-2A BRPI0413906A BRPI0413906A BR PI0413906 A BRPI0413906 A BR PI0413906A BR PI0413906 A BRPI0413906 A BR PI0413906A BR PI0413906 A BRPI0413906 A BR PI0413906A
- Authority
- BR
- Brazil
- Prior art keywords
- hiv
- immunogenic compositions
- mammal
- immunomer
- adjuvant
- Prior art date
Links
- 230000002163 immunogen Effects 0.000 title abstract 8
- 239000000203 mixture Substances 0.000 title abstract 8
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 9
- 239000000427 antigen Substances 0.000 abstract 7
- 102000036639 antigens Human genes 0.000 abstract 7
- 108091007433 antigens Proteins 0.000 abstract 7
- 241000124008 Mammalia Species 0.000 abstract 6
- 239000002671 adjuvant Substances 0.000 abstract 4
- 230000028993 immune response Effects 0.000 abstract 2
- 101710205625 Capsid protein p24 Proteins 0.000 abstract 1
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 abstract 1
- 101710091045 Envelope protein Proteins 0.000 abstract 1
- 101710177166 Phosphoprotein Proteins 0.000 abstract 1
- 101710188315 Protein X Proteins 0.000 abstract 1
- 101710149279 Small delta antigen Proteins 0.000 abstract 1
- 102100022563 Tubulin polymerization-promoting protein Human genes 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
"COMPOSIçõES IMUNOGêNICAS DE HIV, KIT E MéTODOS RELACIONADOS". A invenção fornece composições imunogênicas que aumentam a duração e força da resposta imune em um mamífero. As composições imunogênicas contêm um antígeno de HIV, um imunómero e um adjuvante. O antígeno de HIV pode ser um vírus HIV inteiro morto desprovido da proteína do envelope externo gp120. Alternativamente, o antígeno de HIV pode ser um vírus HIV inteiro morto ou um antígeno p24. Também são fornecidos kits, cujos componentes, quando combinados, produzem as composições imunogênicas da invenção. A invenção também fornece métodos de fabricação das composições imunogênicas pela combinação de um antígeno de HIV, um imunómero e, opcionalmente, um adjuvante. A invenção ainda fornece um método de imunização de um mamífero pela intensificação de uma resposta imune no mamífero pela administração ao mamífero de uma composição imunogênica contendo um antígeno de HIV, um imunómero e, opcionalmente, um adjuvante. Também é fornecido um método de inibição em um mamífero pela administração ao mamífero de uma composição imunogênica contendo um antígeno de HIV, um imunómero e, opcionalmente, um adjuvante.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49880403P | 2003-08-28 | 2003-08-28 | |
PCT/US2004/027995 WO2005021726A2 (en) | 2003-08-28 | 2004-08-27 | Immunogenic hiv compositions and related methods |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0413906A true BRPI0413906A (pt) | 2006-10-24 |
Family
ID=34272731
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0413906-2A BRPI0413906A (pt) | 2003-08-28 | 2004-08-27 | composições imunogênicas de hiv, kit e métodos relacionados |
Country Status (14)
Country | Link |
---|---|
US (2) | US20070253979A1 (pt) |
EP (1) | EP1670893A4 (pt) |
JP (1) | JP2007523884A (pt) |
CN (1) | CN101291691A (pt) |
AP (1) | AP2006003530A0 (pt) |
AU (1) | AU2004269379A1 (pt) |
BR (1) | BRPI0413906A (pt) |
CA (1) | CA2535527A1 (pt) |
CR (1) | CR8251A (pt) |
IL (1) | IL173740A0 (pt) |
MX (1) | MXPA06001996A (pt) |
OA (1) | OA13246A (pt) |
WO (1) | WO2005021726A2 (pt) |
ZA (1) | ZA200602246B (pt) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20030026782A1 (en) | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
EP2241325B1 (en) | 2002-10-29 | 2012-02-08 | Coley Pharmaceutical Group, Inc. | Use of CPG oligonucleotides in the treatment of hepatitis C virus infection |
WO2004053104A2 (en) | 2002-12-11 | 2004-06-24 | Coley Pharmaceutical Group, Inc. | 5’ cpg nucleic acids and methods of use |
JP2008500963A (ja) * | 2004-03-12 | 2008-01-17 | イデラ ファーマシューティカルズ インコーポレイテッド | 第二世代免疫調節性オリゴヌクレオチドを用いて増幅されたhivワクチン活性 |
US8431153B2 (en) | 2008-09-09 | 2013-04-30 | Celebrity Biogens, Llc | Bioactive composition for the treatment of the HIV/AIDS, method for manufacturing and using the same |
JP6034285B2 (ja) * | 2010-05-28 | 2016-11-30 | ゾエティス・ベルジャム・エス・アー | 抗原および免疫調節ワクチンおよびコレステロール、ならびにその使用 |
AP2013007166A0 (en) * | 2011-04-06 | 2013-10-31 | Univ Paris Descartes Inst De Rech Pour Le Dev Ird | Pharmaceutical compositions for preventing and/or treating an HIV disease in humans |
CN107899009B (zh) * | 2011-04-06 | 2021-09-17 | 拜欧瓦克西姆有限公司 | 用于预防和/或治疗人中的hiv疾病的药物组合物 |
US10272143B2 (en) * | 2014-01-08 | 2019-04-30 | Immunovative Therapies Ltd. | Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome |
TWI714529B (zh) * | 2015-05-20 | 2021-01-01 | 以色列商梵提夫免疫療法公司 | 人類免疫缺乏病毒/後天性免疫缺乏症候群之治療 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AP1891A (en) * | 1999-05-06 | 2008-09-23 | The Immune Response Corp | HIV immunogenic compositions and methods. |
CA2435568A1 (en) * | 2001-01-26 | 2002-08-01 | The Immune Response Corporation | Method for treating an hiv-infected individual by combining immunization with structured interruption of anti-retroviral treatment |
KR101126030B1 (ko) * | 2003-07-15 | 2012-03-19 | 이데라 파마슈티칼즈, 인코포레이티드 | 사이토킨 및/또는 화학치료제 또는 방사선 치료와 연계하여면역자극 올리고누클레오티드 및/또는 이뮤노머 화합물을이용하여 면역계를 공동 상승 자극시키는 방법 |
-
2004
- 2004-08-27 CA CA002535527A patent/CA2535527A1/en not_active Abandoned
- 2004-08-27 US US10/570,177 patent/US20070253979A1/en not_active Abandoned
- 2004-08-27 AU AU2004269379A patent/AU2004269379A1/en not_active Abandoned
- 2004-08-27 OA OA1200600064A patent/OA13246A/en unknown
- 2004-08-27 JP JP2006524902A patent/JP2007523884A/ja not_active Withdrawn
- 2004-08-27 US US10/928,642 patent/US20050196411A1/en not_active Abandoned
- 2004-08-27 BR BRPI0413906-2A patent/BRPI0413906A/pt not_active IP Right Cessation
- 2004-08-27 AP AP2006003530A patent/AP2006003530A0/xx unknown
- 2004-08-27 MX MXPA06001996A patent/MXPA06001996A/es not_active Application Discontinuation
- 2004-08-27 WO PCT/US2004/027995 patent/WO2005021726A2/en active Application Filing
- 2004-08-27 CN CNA2004800246538A patent/CN101291691A/zh active Pending
- 2004-08-27 EP EP04782469A patent/EP1670893A4/en not_active Withdrawn
-
2006
- 2006-02-14 IL IL173740A patent/IL173740A0/en unknown
- 2006-02-22 CR CR8251A patent/CR8251A/es not_active Application Discontinuation
- 2006-03-17 ZA ZA200602246A patent/ZA200602246B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2535527A1 (en) | 2005-03-10 |
US20070253979A1 (en) | 2007-11-01 |
AP2006003530A0 (en) | 2006-02-28 |
IL173740A0 (en) | 2006-07-05 |
AU2004269379A2 (en) | 2005-03-10 |
CN101291691A (zh) | 2008-10-22 |
WO2005021726A2 (en) | 2005-03-10 |
US20050196411A1 (en) | 2005-09-08 |
CR8251A (es) | 2008-09-23 |
EP1670893A2 (en) | 2006-06-21 |
WO2005021726A3 (en) | 2008-01-17 |
EP1670893A4 (en) | 2008-09-03 |
OA13246A (en) | 2007-01-31 |
JP2007523884A (ja) | 2007-08-23 |
MXPA06001996A (es) | 2006-06-20 |
ZA200602246B (en) | 2007-05-30 |
AU2004269379A1 (en) | 2005-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0010323A (pt) | Composições imunogênicas, kit e método de confecção da mesma para uso na imunização de um mamìfero | |
NL300897I2 (nl) | Neisseira meningitidis serogroep B recombinant gelipideerd fHbp subfamilie A05 eiwit | |
EA201001189A1 (ru) | Вакцинные композиции, содержащие сапониновый адъювант | |
BRPI0409459A (pt) | novas composições imunogênicas para a prevenção e tratamento de doença meningocócica | |
BRPI0413906A (pt) | composições imunogênicas de hiv, kit e métodos relacionados | |
ATE490262T1 (de) | Abschwächung der immunogenizität von fusionsproteinen | |
WO2004043361A3 (en) | Compositions and methods for the treatment of natural killer cell related diseases | |
IS7658A (is) | Bóluefna samsetningar sem samanstanda af fitufásykrum af L2 og/eða L3 ónæmisgerð úr 1gtB mengishnettlu | |
MXPA02005639A (es) | Induccion de respuestas celulares iinmunologicas al virus de papiloma humano y utilizacion de composiciones de peptidos y acidos nucleico. | |
WO2006068663A3 (en) | Vaccine compositions for treating coronavirus infection | |
BRPI0513681A (pt) | composição que compreendem anticorpo her2, método, formulações farmacêuticas, polipeptìdeo, anticorpo e método de tratamento de cáncer | |
BR0107679A (pt) | Vacina de vesìcula de membrana externa (omv) compreendendo proteìnas de membrana externa do grupo sérico b de neisseria meningitidis | |
ATE419008T1 (de) | Adjuvante zusammensetzung und anwendungsverfahren dafür | |
ES2195169T3 (es) | Vacunas contra calmidias y composiciones inmunogenicas que contienen un antigeno de membrana externa y metodos para su preparacion. | |
EP1471936A4 (en) | HIV VACCINE AND METHOD OF USE | |
MX2007002659A (es) | Composicion vacunal contra el virus de la hepatitis c. | |
EP1556513A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES MEDIATED BY THE HUMANE PAPILLOMA VIRUS | |
RU2008112497A (ru) | Коньюгат для иммунизации и вакцинации и способ повышения иммуногенности | |
BRPI0414073A (pt) | método para induzir uma resposta imune contra infecção por rotavìrus a partir de um sorotipo de rotavìrus, e, uso de uma cepa de rotavìrus atenuado de um sorotipo | |
EA200301125A1 (ru) | Вакцины, включающие в качестве адъюванта интерферон типа i, и связанные с этим способы | |
EA200300535A1 (ru) | Способ получения антигенных структур, усиливающих специфическую перекрестную реактивность | |
BR0313121A (pt) | Composição imunogênica, vacina, métodos de tratamento ou prevenção de doença neisserial, de preparação da composição imunogênica, de preparação da vacina, de preparação de uma imunoglobina para uso na prevenção ou tratamento de infecção neisserial, e de tratamento ou prevenção de infecção neisserial, usos da vacina e da preparação farmacêutica, cepa neisserial geneticamente engenheirada, imunoglobina, e, composição farmacêutica | |
DE60143020D1 (de) | 9-alkylamino-1-nitroacridin-derivate | |
WO2002085409A3 (en) | Methods and compositions for inducing an immune response to an antigen | |
EA200501367A1 (ru) | Вакцинная композиция на основе ганглиозидов для подкожного введения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012. |